Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
5.49
+0.04 (0.73%)
At close: Apr 28, 2026, 4:00 PM EDT
5.49
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:00 PM EDT

Atossa Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Selling, General & Admin
15.9613.514.0412.6111.31
Upgrade
Research & Development
21.1914.1217.3315.089.21
Upgrade
Operating Expenses
37.1427.6231.3827.6920.52
Upgrade
Operating Income
-37.14-27.62-31.38-27.69-20.52
Upgrade
Interest & Investment Income
2.384.054.340.880.01
Upgrade
Other Non Operating Income (Expenses)
-0.01-0.22-0.07-0.15-0.09
Upgrade
EBT Excluding Unusual Items
-34.77-23.79-27.1-26.96-20.61
Upgrade
Gain (Loss) on Sale of Investments
--1.71-2.99--
Upgrade
Pretax Income
-34.77-25.5-30.09-26.96-20.61
Upgrade
Earnings From Continuing Operations
-34.77-25.5-30.09-26.96-20.61
Upgrade
Net Income
-34.77-25.5-30.09-26.96-20.61
Upgrade
Net Income to Common
-34.77-25.5-30.09-26.96-20.61
Upgrade
Shares Outstanding (Basic)
98888
Upgrade
Shares Outstanding (Diluted)
98888
Upgrade
Shares Change (YoY)
2.63%-0.18%-0.43%8.27%934.13%
Upgrade
EPS (Basic)
-4.04-3.04-3.58-3.19-2.64
Upgrade
EPS (Diluted)
-4.04-3.04-3.58-3.19-2.64
Upgrade
Free Cash Flow
-29.79-21.05-20.96-20.79-16.48
Upgrade
Free Cash Flow Per Share
-3.46-2.51-2.49-2.46-2.11
Upgrade
EBITDA
-37.13-27.6-31.35-27.68-20.5
Upgrade
D&A For EBITDA
0.020.020.020.010.02
Upgrade
EBIT
-37.14-27.62-31.38-27.69-20.52
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.